Home > Formulary : Adult > Recent Decisions > 2022 >
Decisions 25th January 2022
At the meeting on the 25th January, the following decisions were agreed
New Drug Requests
Approved
VisuXL Gel (TLS Amber No Shared Care)
-
For aqueous deficiency in moderate to severe dry eyes where other treatments have not been effective
-
Not to be confused with VisuXL drops which contain sodium hyaluronate, not carmellose and is not as cost effective as VisuXL Gel. Note - VisuXL drops are non-formulary.
HyloDual preservative free eye drops (TLS Red)
-
For patients with severe evaporative dry eye disease
Imvaggis Pessary (TLS Green)
-
For the treatment of vulvovaginal atrophy
Please note: the traffic light status of Imvaggis pessary was reviewed and reclassified to TLS blue at the Joint Formulary Group meeting on 26.07.2022 on reflection of the TLS definitions. Imvaggis is an alternative option for vulvovaginal atrophy subject to specific formulary requirements. See menopause guidelines for more information.
Shared Care Protocols
Testosterone Gel (Amber 3 months)
-
The shared care protocol for testosterone gel for treatment of low libido causing distress in women with optimised HRT and with either early menopause (age 45 and under) or surgical menopause only was approved. Testosterone Gel to be included on the Joint Formulary as amber 3 months with the shared care protocol.
TLS Status Changes
Utrogestan capsules for progestogenic opposition of oestrogen HRT
-
Utrogestan capsules changed from TLS blue to green
Other Formulary Decisions
-
Tridestra to be removed from the Joint Formulary
-
Covid Medicines, Sotrovimab, Molnupiravir and Paxlovid to be included on the Joint Formulary as TLS Red under a new formulary subchapter here.
-
Inclisiran TLS changed from green to blue for use in a specific cohort of patients.
Further Work
Thealoz Duo preservative free eye drops
-
The Joint Formulary Group was minded to approve Thealoz Duo for treatment in moderate to severe dry eye disease where there are signs of inflammation as a short course. It is anticipated this will be added to the Joint Formulary as Amber 3 months and this is subject to the finalisation and approval of the BNSSG Dry Eye Disease Guidelines and a shared care protocol. In the meantime, Thealoz Duo remains non-formulary.